{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T19:47:30Z","timestamp":1768420050338,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytarabine is a pyrimidine nucleoside analog that plays a crucial role in the treatment of acute myeloid leukemia. It is typically used in combination with anthracyclines during both induction and consolidation chemotherapy. The well-known side effects of cytarabine include myelosuppression, mucositis, and gastrointestinal disturbances, while cardiotoxicity is rare. Among the cardiovascular effects, sinus bradycardia is uncommon and often underreported. The exact mechanisms behind this condition remain unclear, but several theories have been proposed. These include direct cytotoxic effects on the cardiac conduction system, autonomic imbalance, metabolic or electrolyte disturbances, and immune-mediated hypersensitivity. Most reported cases of bradycardia are transient and asymptomatic, occurring during or shortly after infusion. Delayed or recurrent instances of bradycardia are particularly uncommon.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report the case of a 24-year-old Ethiopian female diagnosed with acute myeloid leukemia who developed delayed and recurrent sinus bradycardia accompanied by transient left ventricular systolic dysfunction during cytarabine therapy. Her initial echocardiographic evaluation showed a normal cardiac function, with a left ventricular ejection fraction of 65%. The first episode of asymptomatic bradycardia occurred approximately 1 month after completing a low-dose cytarabine and doxorubicin induction regimen, accompanied by a transient decrease in left ventricular ejection fraction to 50%, which subsequently normalized. During consolidation therapy with intermediate-dose cytarabine, she experienced a second, more pronounced episode of bradycardia. This episode resolved following the temporary discontinuation of cytarabine and close monitoring. Laboratory evaluations ruled out possible causes of bradycardia including electrolyte abnormalities, thyroid dysfunction, and infection. The Naranjo Adverse Drug Reaction Probability Scale yielded a score of 9, indicating a definite drug-related event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cytarabine-induced sinus bradycardia is a rare but clinically significant adverse event that may occur even in patients without pre-existing cardiac disease or traditional cardiotoxic risk factors. This case is unique for its delayed onset, recurrence upon rechallenge, and transient decline in left ventricular ejection fraction. Clinicians should maintain vigilance for bradyarrhythmias during both induction and consolidation phases of cytarabine therapy, even at lower doses. Awareness of this phenomenon allows timely recognition, avoidance of unnecessary treatment discontinuation, and safe continuation of potentially curative therapy under appropriate cardiac monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-025-05746-6","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T19:02:47Z","timestamp":1765479767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recurrent cytarabine-induced sinus bradycardia in a patient with acute myeloid leukemia: a case report and review of the literature"],"prefix":"10.1186","volume":"20","author":[{"given":"Tsebaot","family":"Tesfaye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4489-1385","authenticated-orcid":false,"given":"Elsa Wolde","family":"Mamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derbe","family":"Assefa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biniyam","family":"Barega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tigist","family":"Seleshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejuma Yadeta","family":"Goshu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"5746_CR1","unstructured":"Vakiti A, Reynolds SB, Mewawalla P. Acute myeloid leukemia. [Updated 2024 Apr 27]. in: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507875\/"},{"issue":"13","key":"5746_CR2","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.3390\/cancers16132474","volume":"16","author":"I Konstantinidis","year":"2024","unstructured":"Konstantinidis I, Tsokkou S, Grigoriadis S, Chrysavgi L, Gavriilaki E. Cardiotoxicity in acute myeloid leukemia in adults: a scoping study. Cancers. 2024;16(13):2474.","journal-title":"Cancers"},{"key":"5746_CR3","volume":"14","author":"K Albsheer","year":"2022","unstructured":"Albsheer K, Fadul A, Khalafalla A, Abdalla EM, Al-Dubai H. Cytarabine-induced bradycardia: a case report. Cureus. 2022;14: e30624.","journal-title":"Cureus"},{"key":"5746_CR4","first-page":"404","volume":"44","author":"M Kumagawa","year":"2003","unstructured":"Kumagawa M, Suzuki K, Nagano M, Takamatsu Y, Suzumiya J, Tamura K. High dose ara-C therapy induced bradycardia in an acute myeloid leukemia patient with inv (16) (p13q22). Rinsho Ketsueki. 2003;44:404\u20136.","journal-title":"Rinsho Ketsueki"},{"key":"5746_CR5","first-page":"320","volume":"18","author":"C Romani","year":"2009","unstructured":"Romani C, Pettinau M, Murru R, Angelucci E. Sinusal bradycardia after receiving intermediate or high dose cytarabine: four cases from a single institution. Eur J Cancer Care. 2009;18:320\u20131.","journal-title":"Eur J Cancer Care"},{"issue":"6","key":"5746_CR6","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1080\/10428190701332456","volume":"48","author":"T Cil","year":"2007","unstructured":"Cil T, Kaplan MA, Altintas A, Pasa S, Isikdogan A. Cytosine-arabinoside induced bradycardia in patient with non-Hodgkin lymphoma: a case report. Leuk Lymphoma. 2007;48(6):1247\u20139. https:\/\/doi.org\/10.1080\/10428190701332456.","journal-title":"Leuk Lymphoma"},{"key":"5746_CR7","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0145-2126(98)00008-3","volume":"22","author":"K Stamatopoulos","year":"1998","unstructured":"Stamatopoulos K, Kanellopoulou G, Vaiopoulos G, Stamatellos G, Yataganas X. Evidence for sinoatrial blockade associated with high dose cytarabine therapy. Leuk Res. 1998;22:759\u201361.","journal-title":"Leuk Res"},{"issue":"3","key":"5746_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jccase.2013.06.002","volume":"8","author":"F Erdem","year":"2013","unstructured":"Erdem F, Bilen Y, \u00c7adirci K, \u00c7ankaya E, Bilen N, G\u00fcndogdu M. Low-dose cytosine arabinoside-induced syptomatic bradycardia in a patient with acute myeloid leukemia. J Cardiol Cases. 2013;8(3):105\u20137. https:\/\/doi.org\/10.1016\/j.jccase.2013.06.002.","journal-title":"J Cardiol Cases"},{"issue":"1","key":"5746_CR9","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.2459\/JCM.0b013e328341d0e5","volume":"16","author":"SA Wayangankar","year":"2015","unstructured":"Wayangankar SA, Patel BC, Parekh HD, Holter JL, Lazzara R. High-dose cytosine arabinoside-induced symptomatic bradycardia. J Cardiovasc Med. 2015;16(1):S38-41. https:\/\/doi.org\/10.2459\/JCM.0b013e328341d0e5.","journal-title":"J Cardiovasc Med"},{"issue":"4","key":"5746_CR10","first-page":"643","volume":"46","author":"M \u015eahin","year":"2024","unstructured":"\u015eahin M, \u00d6zba\u015f B, Kaya A, Miskio\u011flu M, Bayturan \u00d6, Aydo\u011fdu \u0130. High dose cytosine arabinoside-induced asymptomatic bradycardia. Osmangazi T\u0131p Dergisi. 2024;46(4):643\u20136.","journal-title":"Osmangazi T\u0131p Dergisi"},{"issue":"6","key":"5746_CR11","doi-asserted-by":"publisher","first-page":"618","DOI":"10.5152\/akd.2013.213","volume":"13","author":"HU Teke","year":"2013","unstructured":"Teke HU, Karagulle M, Akay OM. High dose cytosin arabinoside induced sinus bradycardia in a Hodgkins lymphoma patient\/Hodgkin lenfomali bir hastada yuksek doz sitozin arabinozid kullanimina bagli gelisen sinus bradikardisi. Anatolian J Cardiol. 2013;13(6):618\u201320. https:\/\/doi.org\/10.5152\/akd.2013.213.","journal-title":"Anatolian J Cardiol"},{"issue":"4","key":"5746_CR12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","volume":"22","author":"VB Pai","year":"2000","unstructured":"Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000;22(4):263\u2013302. https:\/\/doi.org\/10.2165\/00002018-200022040-00002.","journal-title":"Drug Saf"},{"issue":"10","key":"5746_CR13","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s11912-023-01445-x","volume":"25","author":"M Gawlik","year":"2023","unstructured":"Gawlik M, Zimodro JM, G\u0105secka A, Filipiak KJ, Szmit S. Cardiac arrhythmias in oncological patients\u2014epidemiology, risk factors, and management within the context of the new ESC 2022 guidelines. Curr Oncol Rep. 2023;25(10):1107\u201315.","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"5746_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.117.005443","volume":"10","author":"V Buza","year":"2017","unstructured":"Buza V, Rajagopalan B, Curtis AB. Cancer treatment-induced arrhythmias: focus on chemotherapy and targeted therapies. Circ Arrhythm Electrophysiol. 2017;10(8): e005443. https:\/\/doi.org\/10.1161\/CIRCEP.117.005443.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"5746_CR15","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et\u00a0al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239\u201345. https:\/\/doi.org\/10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05746-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-025-05746-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-025-05746-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T11:21:01Z","timestamp":1768389661000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-025-05746-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5746"],"URL":"https:\/\/doi.org\/10.1186\/s13256-025-05746-6","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}